KiSS1 metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to Akt, tumor necrosis factor family ligand expression, and apoptosis.
Navenot. Jean-Marc JM; Fujii. Nobutaka N; Peiper. Stephen C SC
Key Findings
- GPR54 activation by kisspeptin‑10 suppresses Akt signaling from EGFR and insulin receptors
- Cell death is driven by ERK‑dependent TNF‑α and FasL expression, not by Akt inhibition
- Both autocrine (direct on tumor cells) and paracrine (via surrounding stromal cells) anti‑metastatic effects are suggested
Practical Outcomes
- The results are interesting for future cancer‑drug research, but they don’t translate into a usable protocol for longevity or metabolic health. No dosage, safety, or human data are provided, so biohackers should wait for further studies before considering any self‑experimentation.
Summary
Kisspeptin-10 activates a receptor called GPR54, which blocks growth signals from epidermal growth factor and insulin receptors and triggers cell death mainly through an ERK‑driven inflammation pathway. This could help stop cancer cells from spreading, but the work was done in lab cell lines and gives no human dosing or safety guidance.
Abstract
The powerful metastasis suppressor function of KiSS1 gene products has been demonstrated in both clinical studies and experimental models, but its mechanism is still incompletely understood. Studies on the antimetastatic function of KiSS1 and GPR54 largely focused on the autocrine inhibition of cell motility, despite experimental evidence of an alternative post-migratory effect. We showed previously that the activation of its cognate receptor GPR54 by kisspeptin-10 suppressed the capacity of the prometastatic chemokine receptor CXCR4 to induce chemotaxis in response to stromal cell derived factor 1 and abolished the activation of Akt by CXCR4. We demonstrate here that activation of GPR54 can also abolish the activation of Akt by the tyrosine kinase receptors for epidermal growth factor and insulin. The signaling of GPR54 was sufficient to trigger apoptosis in epithelial and lymphoid cell lines. Surprisingly, this phenomenon depended largely on the activation of extracellular signal-regulated kinase (ERK) rather than the inhibition of Akt. Activation of GPR54 resulted in the ERK-dependent expression of tumor necrosis factor-alpha and FasL in a lymphoid cell line, the latter being the main trigger of apoptosis. These data provide novel mechanisms relevant to a potential autocrine metastasis suppression effect of KiSS1 on GPR54-positive tumor cells. More importantly, they also establish an experimental basis for a paracrine mode of action by which kisspeptins suppress the metastatic potential of tumor cells lacking expression of the receptor, as observed in several animal models of metastasis. The action on stromal cells significantly broadens the clinical relevance of this metastasis suppressor.
Study Information
pubmed
2009
2009-02-06T00:00:00.000Z
10.1124/mol.108.054270
45
44